An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often used in cancer and vaccine treatments, by using drugs already approved by the FDA for unrelated conditions.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Voters in November pushed Colorado to the forefront of a psychedelic-assisted therapy movement for mental health, becoming the second state behind Oregon to approve the use of hallucinogenic mushrooms for therapeutic use. Click here to […]
GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet receives $1.5 million grant from USAID to evaluate use of needle-free delivery in routine polio immunization Click here to view original post
A new study led by researchers from the University of Colorado Anschutz Medical Campus and the National Institute for Occupational Safety and Health (NIOSH) through the Centers for Disease Control and Prevention (CDC) finds that […]
Copyright © 2026 Biotech Networks
